Browse the corpus

©2013 UpToDate ® Print Email Available insulins Type Onset (Hrs) Peak (Hrs) Duration (Hrs) Comments Rapid-acting Lispro Insulin 0.25 1 2-3 No rapid-acting insulin should be used intravenously- rapid action is a result of rapid release from subcutaneous tissues Insulin Aspart 0.25 1 2-3 Glulisine 0.25 1 2-3 Approved, to be marketed shortly Short-Acting Regular Human Insulin 0.5-1 2-4 4-6 Longer action if larger dose (mass action effect) Intermediate-Acting NPH Human 0.5-1 4-6 8-16 Peak and duration quite (Neutral Protamine variable Hagedorn)* Long-Acting Insulin Glargine 0.5-1 none 23-26 Basal insulin-minimal or no peak- cannot be mixed with other insulins-clear insulin forms crystals at in vivo pH * Mixed insulins consisting of NPH and regular (70:30 mix) or NPH and Lispro (75:25 mix) as well as other concentrations and mixes are sometimes useful. Other new insulins are presently in clinical trials. An inhaled short-acting insulin preparation has received provisional approval by the FDA for use in adults but is not yet released.